Novo Nordisk receives Investment Bank Analyst Rating Update
- ByInvesting.com-
Novo Nordisk A/S (NYSE: NVO) reported Q4 FY22 sales of DKK 48.09 billion, up 25% Y/Y (+18% on constant currency), driven by Diabetes care sales growth of 14% (CER) and Obesity care...
Novo Nordisk global sales were driven by diabetes and obesity care sales.
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Converting mutual funds to ETFs is an emerging trend ETFs offer flexible trading and more transparency 2 JP Morgan ETFs worth a look The conversion of mutual funds into...
Inflation worries continue to weigh on equity markets Earnings season will likely increase volatility ETFs offer investors ability to diversify Earnings season has started with...
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
| Average | 962.22 (+2.20% Upside) |
| High | 1,200.00 |
| Low | 540.00 |
| Price | 941.50 |
| No. of Analysts | 27 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Buy | Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Sell | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 5.79 | 5.81 | 5.56 | +0.040 | +0.70% | 4.94M | Sydney | |||
| 0.005 | 0.005 | 0.005 | 0.00 | 0.00% | 143.05K | Sydney | |||
| 0.023 | 0.028 | 0.023 | -0.002 | -8.00% | 1.49M | Sydney | |||
| 18.15 | 18.22 | 18.02 | +0.17 | +0.95% | 2.78M | Sydney | |||
| 0.18 | 0.19 | 0.175 | 0.00 | 0.00% | 3.04M | Sydney | |||
| 3.55 | 3.56 | 3.52 | +0.010 | +0.28% | 1.27M | Sydney | |||
| 0.015 | 0.015 | 0.014 | 0.00 | 0.00% | 2.46M | Sydney | |||
| 7.67 | 7.71 | 7.59 | +0.05 | +0.66% | 1.26M | Sydney | |||
| 3.02 | 3.14 | 3.02 | -0.110 | -3.51% | 801.39K | Sydney | |||
| 8.22 | 8.29 | 7.95 | +0.050 | +0.61% | 8.07M | Sydney | |||
| 0.44 | 0.44 | 0.43 | -0.010 | -2.22% | 122.50K | Sydney | |||
| 0.08 | 0.08 | 0.078 | +0.001 | +1.27% | 2.57M | Sydney | |||
| 3.33 | 3.43 | 3.31 | 0.00 | 0.00% | 889.60K | Sydney | |||
| 0.004 | 0.004 | 0.003 | -0.001 | -12.50% | 626.05K | Sydney | |||
| 0.086 | 0.086 | 0.082 | +0.004 | +4.88% | 10.98M | Sydney |